Classification of kinase inhibitors using a Bayesian model

Journal of Medicinal Chemistry

Volumn 47, Issue 18, 2004, Pages 4463-4470

  Xia, Xiaoyang ^a   Maliski, Edward G ^a   Gallant, Paul ^a   Rogers, David ^b  

^a AMGEN INC   (United States)

^b SciTegic Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHOTRANSFERASE INHIBITOR; PROTEIN SERINE THREONINE KINASE; PROTEIN SERINE THREONINE KINASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; BAYES THEOREM; CALCULATION; DRUG ACTIVITY; DRUG CLASSIFICATION; DRUG STRUCTURE; ENZYME INHIBITION; PREDICTION; PROTEIN TARGETING; STATISTICAL MODEL; STRUCTURE ACTIVITY RELATION;

ARTIFICIAL INTELLIGENCE; BAYES THEOREM; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; HUMANS; PHOSPHOTRANSFERASES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 4143122120     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0303195     Document Type: Article

References (28)

1. Woolfrey, J. R.; Weston, G. S. The Use of Computational Methods in the Discovery and Design of Kinase Inhibitors. Curr. Pharm. Des. 2002, 8, 1527-1545.
2. Majeux, N.; Scarsi, M.; Tenette-Souaille, C.; Caflisch, A. Hydrophobicity Maps and Docking of Molecular Fragments With Solvation. Perspect. Drug Discovery Des. 2000, 20, 145-169.
3. Dumas, J. Protein Kinase Inhibitors: Emerging Pharmacophores 1997-2000. Exp. Opin. Ther. Pat. 2001, 11, 405-429.
4. Toledo, L. M.; Lydon, N. B.; Elbaum, D. The Structure-Based Design of ATP-Site Directed Protein Kinase Inhibitors. Curr. Med. Chem. 1999, 6, 775-805.
5. Willett, P.; Wintermann, V.; Bawden, D. Implementation of Nonhierarchic Cluster Analysis Methods in Chemical Information System: Selection of Compounds for Biological Testing and Clustering of Substructure Search Output. J. Chem. Inf. Comput. Sci. 1986, 26, 109-118.
6. Brown, R. D.; Martin, Y. C. Use of Structure-Activity Data to Compare Structure Based Clustering Methods and Descriptors for Use in Compound Selection. J. Chem. Inf. Comput. Sci. 1996, 36, 572-584.
7. Brown, R. D.; Martin, Y. C. The Information Content of 2D and 3D Structural Descriptors Relevant to Ligand-Receptor Binding. J. Chem. Inf. Comput. Sci. 1997, 37, 1-9.
8. Pirard, B.; Picket, S. D. Classification of Kinase Inhibitors Using BCUT Descriptors. J. Chem. Inf. Comput. Sci. 2000, 40, 1431-1440.
9. Pearlman, R. S.; Smith, K. M. Novel Software Tools for Chemical Diversity. Perspect. Drug Discovery Des. 1998, 9, 339-353.
10. Stanton, D. T. Evaluation and Use of BCUT Descriptors in QSAR and QSAP Analysis. J. Chem. Inf. Comput. Sci. 1999, 39, 11-20.
11. Gasteiger, J.; Zupan, J. Neural Networks in Chemistry. Angew. Chem., Int. Ed. Engl. 1993, 32, 503-536.
12. Burden, F. R. Using Artificial Neural Networks to Predict Biological Activity from Simple Molecular Structural Considerations. Quant. Struct.-Act. Relat. 1996, 15, 7-11.
13. King, R. D.; Hirst, J. D.; Sternberg, M. J. E. New Approaches to QSAR: Neural Networks and Machine Learning. Perspect. Drug Discovery Des. 1993, 1, 279-290.
14. Rogers, D.; Hopfinger, A. J. Application of Genetic Function Approximation to Quantitative Structure-Activity Relationships and Quantitative Structure-Property Relationships. J. Chem. Inf. Comput. Sci. 1994, 34, 854-866.
15. Gillet, V. J.; Willett, P.; Bradshaw, J. Identification of Biological Activity Profiles Using Substructural Analysis and Genetic Algorithms. J. Chem. Inf. Comput. Sci. 1998, 38, 165-179.
16. Martin, Y. C. Quantitative Drug Design; Marcel Dekker: New York. 1978.
17. Ramsden, C. A. Quantitative Drug Design. In Comprehensive Medicinal Chemistry; Hansch, C., Ed.; Pergamon Press: New York, 1990; Vol. 4.
18. Dunn, W. J. Quantitative Structure-Activity Relationships. In Drug Discovery Technologies; Clark, C. R.; Moos, W. H., Ed.; Ellis Horwood Limited: New York, 1990; Chapter 2.
19. Zhu, L. L.; Hou, T. J.; Chen, L. R.; Xu, X. J. 3D QSAR Analysis of Novel Tyrosine Kinase Inhibitors Based on Pharmacophore Alignment. J. Chem. Inf. Comput. Sci. 2001, 41, 1032-1040.
20. Rusinko, A., III; Farmen, M. W.; Lambert, C. G.; Brown, P. L.; Young, S. S. Analysis of a Large Structure/Biological Activity Data Set Using Recursive Partitioning. J. Chem. Inf. Comput. Sci. 1999, 39, 1017-1026.
21. Chen, X.; Rusinko, A., III; Young, S. S. Recursive Partitioning Analysis of a Large Structure-Activity Data Set Using Three-Dimensional Descriptors. J. Chem. Inf. Comput. Sci. 1998, 38, 1054-1062.
22. Manallack, D. T.; Pitt, W. R.; Gancia, E.; Montana, J. G.; Livingstone, D. J.; Ford, M. G.; Whitley, D. C. Selecting Screening Candidates for Kinase and G Protein-Coupled Receptor Target Using Neural Networks. J. Chem. Inf. Comput. Sci. 2002, 42, 1256-1262.
23. Cramer, R. D. Patterson, D. E.; Bunce, J. D. Comparative Molecular Field Analysis (CoMFA). 1. Effect of Shape on Binding of Steroids to Carrier Proteins. J. Am. Chem. Soc. 1988, 110, 5959-5967.
24. Clark, M.; Cramer, R. D.; Jones, D. M.; Patterson, D. E.; Simeroth, P. E. Comparative Molecular Field Analysis (CoMFA). 2. Toward its Use With 3-D Structural Databases. Tetrahedron Comput. Methodol. 1990, 3, 47-59.
25. Cramer, R. D.; Wold, S. B. US Patent 5,025, 388, June 18, 1991.
26. http://www.daylight.com/support.
27. Young, S. S.; Lam, R. L.; Welch, W. J. Initial Compound Selection for Sequential Screening. Curr. Opin. Drug Discovery Dev. 2002, 5, 422-427.
28. Engels, M. F. M.; Venkatarangan, P. Smart Screening: Approach to Efficient HTS. Curr. Opin. Drug Discovery Dev. 2001, 4, 275-283.